NCT03758664招募中1 期
A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 56
- 试验地点
- 7
- 主要终点
- Adverse events(Phase 1 dose escalation)
研究概览
简要总结
Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.
详细描述
The study consisted of a screening period, a treatment period with 21 days of repeated treatment per cycle (duration treatment with ICP-192), and a follow-up period (28 days after last dose). The recruited patients receive a single dose on day 1, then after a 3-day washout period, repeated dosing will be followed. The starting dose is 2 mg, QD, and dose escalation will follow accelerated titration and modified 3+3 dose-finding schema. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (21-day cycle).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An unresectable or metastatic advanced malignant solid tumor confirmed by histopathology that has failed to respond to known treatment or has recurred;Subjects who progress under standard treatment, are intolerant to standard treatment, or do not have standard treatment (dose escalation phase)
- •Tissue or cell pathology confirmed unresectable, recurrent or metastatic (AJCC version 8 TNM staging IV (2017), biliary tract malignant tumor, or intolerance to first-line chemotherapy failure (twice (defined as reduction still cannot tolerate) first-line chemotherapy, neoadjuvant/progress/adjuvant chemotherapy after 6 months recurrence can be selected (dose extension stage); - At least one evaluable disease according to RECIST1.1
- •FGFR2 translocation/fusion has been reported or FGFR2 translocation/fusion has been detected in central laboratory (dose extension phase);
- •Age ≥18 and ≤75
- •There is at least one evaluable lesion according to RECIST1.1 criteria
- •ECOG strength score is 0-1 (dose escalation stage), and ECOG strength score is 0-2 (dose expansion stage).
- •The expected survival time is more than 3 months
- •The organ function level must meet the following requirements (subject to the upper limit of normal value in the clinical trial center):
- •A) bone marrow: absolute count of neutrophils (ANC)≥1.5*109/L (1500/mm3), platelet ≥75*109/L, hemoglobin ≥9g/dL; B) coagulation function: international standardized ratio of prothrombin time and partial thrombin time <1.5 times the upper limit of normal value; C) liver: serum bilirubin ≤1.5 times the upper limit of normal value (tumor involvement in the liver ≤2.5 times the upper limit of normal value), aspartic aminotransferase (AST) and alanine aminotransferase (ALT)≤3 times the upper limit of normal value (AST and ALT≤5 times the upper limit of normal value in the case of liver metastasis); D) serum creatinine ≤1.5 times the upper limit of normal value, or creatinine clearance ≥70mL/min (calculated according to the Cockroft-gult formula).
- •Volunteer to enroll and sign informed consent to follow the treatment protocol and visit plan.
排除标准
- •Previous treatment with FGFR small molecule inhibitors or antibody drugs.
- •Anti-cancer therapy, such as chemotherapy (except for oral fluorouracil), immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-192, oral fluorouracil agents within two weeks of the first dose of ICP-
- •Major surgery within 6 weeks of the first dose of ICP-
- •Blood phosphate persistently above ULN with intervene therapy within two weeks of the first dose of ICP-
- •Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-
- •Central nervous system (CNS) metastasis
- •Current clinically significant cardiovascular disease including:
- •Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
- •Known active bleeding within 2 months of screening or 6 months of bleeding history.
- •According to the investigator's judgement, there are evidences of a serious or uncontrollable systemic disease (such as unstable or uncompensated respiratory, liver or kidney disease); or any unstable systemic disease (including active clinically serious infections, uncontrolled hypertension, liver and kidney or metabolic diseases)
- •History of interstitial pneumonia, deep vein thrombosis, pulmonary embolism. Stroke or intracranial hemorrhage within 6 months before the first dose of ICP-
- •History of organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Any corneal or retinal abnormalities that may increase ocular toxicity, including but not limited to:
- •History of central serous retinopathy (CSR) or retinal vein occlusion (RVO) disease or has related diseases;
- •Active age-related macular degeneration (AMD);
- •Diabetic retinopathy with macular edema;
- •Uncontrollable glaucoma;
- •Keratonosus, such as Keratitis, keratoconjunctivitis, keratopathy, corneal wear, inflammation or ulceration.
- •Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
- •Any toxicities must recover to ≤ Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting).
- •Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.
- •Investigators believe that the patients are not eligible for enrollment for the other reasons.
研究组 & 干预措施
ICP-192
Experimental
The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
干预措施: ICP-192 (Drug)
结局指标
主要结局
Adverse events(Phase 1 dose escalation)
时间窗: From the time a signed and dated ICF until 28 days after last dose of study drug
Adverse events graded by CTCAE V5.0 as a measurement of the safety and tolerability profile of ICP-192
Objective Response Rate(ORR)(Phase 2a dose expansion)
时间窗: At the end of Cycle 4(each cycle is 21 days)
Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).
次要结局
- Cmax(At the end of Cycle 1(each cycle is 21 days))
- Food effect(Day 1 - 6 after single dose)
- Objective Response Rate(ORR) (Phase 1 dose escalation)(At the end of Cycle 4(each cycle is 21 days))
- AUC(At the end of Cycle 1(each cycle is 21 days))
- Apparent half-life for designated elimination phases (t½)(At the end of Cycle 1(each cycle is 21 days))
- Disease control rate(DCR)(At the end of Cycle 4(each cycle is 21 days))
- Duration of Objective Response (DOR)(At the end of Cycle 4(each cycle is 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 4(each cycle is 21 days))
- Correlationship between FGFR aberrations with efficacy. (Phase 2a dose expansion)(At the end of Cycle 4(each cycle is 21 days))
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected MalignanciesSolid Tumors, Advanced Solid TumorsNCT01987362Hoffmann-La Roche52
进行中（未招募）
2 期
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsAdvanced Solid TumorsCRPCmCRPCMetastatic Castrate-resistant Prostate CancerPT-112Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteProstatic NeoplasmsNCT02266745Promontory Therapeutics Inc.109
已完成
1 期
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759Non Small Cell Lung CancerNCT03360929LYZZ Alpha Holding Ltd15
招募中
1 期
A Clinical Study of SHR-9539 in Patients With Multiple MyelomaMultiple MyelomaNCT06484777Suzhou Suncadia Biopharmaceuticals Co., Ltd.138
招募中
1 期
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid TumorsSolid TumorNon-small Cell Lung CancerNCT06612840Sichuan Baili Pharmaceutical Co., Ltd.20